Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q3 2017 · 10-Q
Revenue$45.66M$45.66M+111.2% vs Q3 2016 Net Income$67.36M$67.36M+6,309.3% vs Q3 2016 EPS Diluted$2.80$2.80+5,500.0% vs Q3 2016 Operating Income$16,493,000+201.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$27,629,000+55.6% Margins · derivedOperating margin36.1%+10.8 pt vs Q3 2016
Net margin147.5%+142.7 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 9, 2017 · 40 d after period end